S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News

$12.18
-0.53 (-4.17%)
(As of 09/20/2023 ET)
Compare
Today's Range
$12.17
$12.74
50-Day Range
$12.18
$15.02
52-Week Range
$11.09
$22.11
Volume
781,149 shs
Average Volume
1.24 million shs
Market Capitalization
$1.30 billion
P/E Ratio
12.06
Dividend Yield
N/A
Price Target
$24.75

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
103.2% Upside
$24.75 Price Target
Short Interest
Bearish
7.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.85mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
68.97%
From $0.87 to $1.47 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

94th out of 961 stocks

Pharmaceutical Preparations Industry

29th out of 454 stocks


CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Price History

CPRX Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
3 Pharma Stocks to Watch for Value in September
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
3 Value Pharma Stocks to Keep Watching
5 Analysts Have This to Say About Catalyst Pharmaceuticals
H.C. Wainwright Keeps Their Buy Rating on Catalyst Pharma (CPRX)
Where Catalyst Pharmaceuticals Stands With Analysts
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
8/09/2023
Today
9/21/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
82
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$24.75
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+103.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$83.08 million
Pretax Margin
47.81%

Debt

Sales & Book Value

Annual Sales
$214.20 million
Cash Flow
$0.78 per share
Book Value
$2.89 per share

Miscellaneous

Free Float
93,695,000
Market Cap
$1.30 billion
Optionable
Optionable
Beta
1.11

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Patrick J. McEnanyMr. Patrick J. McEnany (Age 76)
    Co-Founder, Chairman, Pres & CEO
    Comp: $1.2M
  • Ms. Alicia Grande C.M.A.Ms. Alicia Grande C.M.A. (Age 52)
    CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO
    Comp: $667.91k
  • Dr. Steven R. Miller Ph.D.Dr. Steven R. Miller Ph.D. (Age 61)
    COO & Chief Scientific Officer
    Comp: $809.03k
  • Dr. Gary Ingenito M.D. (Age 67)
    Ph.D., Chief Medical & Regulatory Officer
    Comp: $751.85k
  • Mr. Jeffrey Del Carmen (Age 52)
    Chief Commercial Officer
    Comp: $711.7k
  • Ms. Mary Coleman
    VP & Head of Investor Relations
  • Mr. Brian Elsbernd J.D. (Age 59)
    Chief Compliance Officer & Chief Legal Officer
  • Mr. Pete Curry Sr.
    VP of Sales
  • Dr. Stanley Iyadurai M.D.
    Ph.D., Sr. VP of Medical Affairs & Drug Discovery
  • Dr. Preethi Sundaram Ph.D. (Age 47)
    Chief Strategy Officer













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 12-month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $24.00 to $27.00. On average, they expect the company's share price to reach $24.75 in the next year. This suggests a possible upside of 103.2% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX shares have decreased by 34.5% and is now trading at $12.18.
View the best growth stocks for 2023 here
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 7,160,000 shares, an increase of 6.1% from the August 15th total of 6,750,000 shares. Based on an average daily trading volume, of 1,510,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 7.2% of the shares of the stock are sold short.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.25 by $0.08. The biopharmaceutical company earned $99.58 million during the quarter, compared to the consensus estimate of $92.77 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 36.13% and a net margin of 38.14%.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.00 million-$390.00 million, compared to the consensus revenue estimate of $380.21 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.88%), State Street Corp (8.87%), Dimensional Fund Advisors LP (2.32%), Geode Capital Management LLC (1.81%), Northern Trust Corp (1.32%) and Goldman Sachs Group Inc. (1.17%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $12.18.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.30 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $1.01 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -